Date: June 2019 | Category: Type 1 Diabetes Mellitus | Type 2 Diabetes Mellitus |
Summary
This Position Statement represents the collective views of the Australian Diabetes Society, the Australian Diabetes Educators Association and Diabetes Australia.
The Therapeutic Goods Administration (TGA) recently approved the first “biosimilar” insulin product for use in Australia – Basaglar Insulin. A “biosimilar” is a copy of a biological molecule that has already been approved for use and has a demonstrated similarity in physiological characteristics, efficacy and safety.
Position Statement
Download the full version of the ‘Use of “biosimilar” Insulins for Diabetes Position Statement’ – PDF (Updated: June, 2019)
